Publications by authors named "T W Mattingly"
Estimating a Drug's Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold.
Appl Health Econ Health Policy
January 2025
Article Synopsis
- Many cost-effectiveness analyses of pharmaceuticals ignore future price changes that occur when generic competition enters, mainly due to uncertainty in estimating post-exclusivity prices.
- The study investigates whether a drug's post-loss-of-exclusivity price can be reliably estimated using its cost of goods sold (COGS) by analyzing manufacturer profit margins and engaging stakeholders.
- Results show that COGS were successfully estimated for 2168 drugs, with a median price of $0.10 per tablet/capsule, leading to a method to estimate future prices that could enhance cost-effectiveness evaluations.
Background: Underlying intracranial stenosis is the most common cause of failed mechanical thrombectomy in patients with acute ischemic stroke with large vessel occlusion. Adjunct emergent stenting is sometimes performed to improve or maintain reperfusion, despite limited data regarding its safety or efficacy.
Methods: We conducted a prospective multicenter observational international cohort study.